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Peroulis M., Kakisis J., Kapelouzou A., Giagini A., Giaglis S., Mantziaras G.,
Kostomitsopoulos N., Karayannacos P., Macheras A. Eur J Vasc Endovasc
Surg 2010;40:216–23.
Objectives: To test the hypothesis that vein graft intimal hyperplasia
can be significantly suppressed by a single intra-operative transfection of the
graft with a decoy oligonucleotide (ODN) binding the transcription factor
Egr-1.
Design: Experimental study.
Materials and methods: Jugular vein to carotid artery interposition
grafts in rabbits were treated with Egr-1 decoy, mutant decoy ODN, vehicle
alone, using a non-distending pressure of 300 mmHg for 20 min, or were
left untreated. All animals were fed a 2% cholesterol diet. The animals were
sacrificed after 48 h, 6 weeks and 12 weeks. Paraffin-embedded vein sections
were subjected to angiometric analysis.
Results: Successful delivery of the ODN was confirmed by DAPI
staining. Quantitative real-time PCR revealed a 60% decrease of the Egr-1
gene expression in the animals in which the Egr-1 decoy ODN was deliv-
ered. Cellular proliferation was also significantly decreased as indicated by
the Ki-67 labelling index. An increase in intimal and medial thickness was
found in all vein grafts. However, intimal thickness was significantly reduced
in the grafts treated with Egr-1 decoy ODN, whereas luminal area was
significantly increased.
Conclusion: A single intra-operative pressure-mediated transfection of
vein grafts with Egr-1 decoy ODN significantly suppresses intimal hyperpla-
sia in a rabbit hypercholesterolaemic model.
Stenting for Chronic Post-thrombotic Vena Cava and Iliofemoral
Venous Occlusions: Mid-term Patency and Clinical Outcome
Rosales A., Sandbæk G., Jørgensen J.J. Eur J Vasc Endovasc Surg 2010;40:
234–40.
Objectives: The aim of this study was to determine the mid-term
patency and the clinical outcome after stenting of chronic occluded caval and
iliofemoral venous segments.
Design: Observational study.
Material/methods: During the period 2000 and 2009, 2400 patients
with chronic venous insufficiency (CVI) were evaluated, and 34 with chronic
venous occlusions after deep venous thrombosis (DVT) were selected for
endovascular treatment. The median age was 41 (range 15–63) years, and
19 were female. The following investigations were undertaken: colour
duplex ultrasound (CDU), ascending venography (AV), venous occlusionReaders can access EJVES articles at http://intl.evenous claudication, oedema, pain and ulcer. All patients were treated by
stenting occluded segments. Self-expanding stents were deployed in 22
iliofemoral, nine iliac and one caval-iliac-femoral. Twenty-one procedures
required stenting across the inguinal ligament.
Results: Primary recanalisation was accomplished in 32/34 (94%). The
median follow-up was 33 months (1–96) with clinical examination, CDU
and VOP. Two-year primary patency was 14/21 (67%), primary-assisted
patency 16/21(76%), and secondary patency was 19/21 (90%). Venous
claudication and oedema resolved in those successfully recanalised. Four of
the seven ulcers healed.
Conclusion: Stenting to treat venous claudication, oedema and recur-
rent venous ulcer caused by post-thrombotic chronic venous occlusions has
positive clinical outcome and good mid-term patency.
Laser and Radiofrequency Ablation Study (LARA study): A Random-
ised Study Comparing Radiofrequency Ablation and Endovenous La-
ser Ablation (810 nm)
Goode S.D., Chowdhury A., Crockett M., Beech A., Simpson R., Richards T.,
Braithwaite B.D. Eur J Vasc Endovasc Surg 2010;40:246–53.
Objectives: There have been few randomised studies comparing Ra-
diofrequency Ablation(RFA) with other endovenous techniques. The pri-
mary aim of this study was to determine whether RFA of the great saphenous
vein (GSV) was associated with less pain and bruising than endovenous laser
ablation (EVLA).
Materials and methods: This trial had two cohorts – patients with
bilateral GSV incompetence causing varicose veins (VV) and those with
unilateral GSV VVs. In total 87 legs were treated in this study. Limbs in the
bilateral group were treated with RFA in one leg and EVLA in the other. In
the unilateral group limbs were randomised to RFA or EVLA. RFA was
performed using the Celon RFiTT system (Teltow, Germany). EVLA was
performed using an 810 nm Laser (Biolitec AG, Germany). Phlebectomies
were performed as required. Primary endpoints were patient assessed pain
and bruising measured by visual analogue scale (VAS). Secondary endpoints
were patency assessed by duplex ultrasound at 6 weeks and 6 months.
Results: In the bilateral group, RFA resulted in significantly less pain
than EVLA on days 2–11 postoperatively. RFA also resulted in significantly
less bruising than EVLA on days 3–9. There were no significant differences
in mean post operative pain, bruising and activity scores in the unilateral
group. Both RFA and EVLA resulted in occlusion rates of 95% at 10 days
postoperatively.
Conclusions: RFA was less painful for patients than EVLA and pro-
plethysmography (VOP), venous pressure gradient (VPG) and CT venog-
raphy or trans-femoral/popliteal venography. The major symptoms were
duced less bruising in the postoperative period with comparable success rates
but there was no difference in the unilateral group.lsevierhealth.com/journals/ejvs/default.cfm
